Christoph Nerl

TL;DR: The results of this prospective study suggest a substantial impact on outcome for upfront autoSCT in PTCL and should be further evaluated in randomized trials.

TL;DR: Dynamic data acquisition combined with Patlak analysis of FDG kinetics may provide superior information in therapy monitoring andFDG uptake at 42 days after therapy was superior in prediction of long-term outcome over day 7 parameters.

TL;DR: Early high-dose therapy followed by rapid adaptation to good tolerability increases the rate of major molecular remission (MMR) at 12 months, and achievement of MMR by month 12 is directly associated with improved survival.

TL;DR: Interestingly, receptor cross-linking caused by incubation of cells with anti-CXCR4 mAb triggers receptor trafficking, in that the receptor is rapidly internalized and recycled to the cell surface, therefore, receptor internalization and recycling may regulate the functional interaction of the receptor with envelope proteins during an initial step of HIV-1 infection.

TL;DR: MR(4.5) is a new molecular predictor of long-term outcome, is reached by a majority of patients treated with imatinib, and is achieved more quickly with optimized high-dose imatin ib, which may provide an improved therapeutic basis for treatment discontinuation in CML.